MCBD (880750)

  https://cordis.europa.eu/project/id/880750

  Horizon 2020 (2014-2020)

  MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

  SME instrument (EIC-SMEInst-2018-2020)

  biomolecules  ·  microscopy  ·  oncology  ·  personalized medicine  ·  histology

  2019-10-01 Start Date (YY-MM-DD)

  2023-01-31 End Date (YY-MM-DD)

  € 2,290,000 Total Cost

  Description

Biopsy is a commonly used medical procedure for the diagnosis and characterization of cancer and other diseases. Traditionally, the tissue obtained is preserved by formalin fixation, embedded in paraffin, sectioned to thin tissue layers, and then analysed histologically under the microscope to evaluat overall tissue morphology. Current advancement in biomedicine makes it possible for greater use of molecular technologies. These technologies, allow for analysis of change in biomolecules (biomarkers) during cancer progression rather than tissue morphology alone. Laboratory analysis of biomarkers require tissue to be fresh (or fresh frozen) and rather not be preserved by formalin. In order to yield viable biomarker analysis tissue must be frozen as soon as possible because biomarkers are extremely sensitive to degradation. Current biopsy devices are not designed to meet these challenges of rapid freezing as a replacement to formalin fixation. We, at Sorek Medical Systems Ltd., a 16-year-old R&D company based in Israel, developed two biopsy devices that automatically split the tissue sample in two during biopsy acquisition. Our technology allows chemical standard formalin fixation for histology. Sorek’s devices will be used by radiologists and surgeons, and by pharmaceutical companies seeking the development of biomarker-targeting drugs with the goal of improving personalized medicine and improving early diagnosis for breast, lung, chest, prostate, and other organs’ cancer disease. Our CryoBiopsy Phase 2 project will allow us to test and validate our devices which will require € 2.8 million investment. Our financial forecast show that after five-year commercialization we will generate a cumulative revenues of €57 million and will create 20 positions which will include engineers, technicians and our own sales personnel

  Complicit Organisations

1 Israeli organisation participates in MCBD.